Connect Biopharma is trading 5% up at $2.90, supported primarily by investor anticipation of September topline results from the Phase 2 Seabreeze STAT asthma and COPD studies.
- The company expects to report the results this month.
- Shares gained 16.95% on September 2 and 7.27% on September 1.
- Biotech-sector strength is also supportive, with XBI up 2.75%; no new company-specific announcement was identified on September 3.